Status:
COMPLETED
Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer
Lead Sponsor:
Maastricht Radiation Oncology
Collaborating Sponsors:
The Netherlands Cancer Institute
Maastricht University Medical Center
Conditions:
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Radiotherapy in combination with different forms of immune therapy improved consistently local tumor control and very interestingly, lead to better systemic tumor control and the induction of specific...
Detailed Description
Radiation has consistently been shown to activate key elements of the immune system. Radiotherapy in combination with different forms of immune therapy such as anti-PD-(L)1, anti-CTLA4,immunocytokines...
Eligibility Criteria
Inclusion
- Stage IV non-small cell lung cancer
- Initially a Complete Remission, Partial Remission or Stable Disease under immune therapy alone or concurrent immune therapy and chemotherapy and now progressive disease
- Able to continue the immune therapy
Exclusion
- Not able to continue the already initiated immune therapy
- Patients with any grade 3 toxocity
- Patients in whom radiotherapy cannot be delivered, according to the radiation oncologist at the multi-disciplinary patient discussion
Key Trial Info
Start Date :
July 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2023
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT03406468
Start Date
July 15 2019
End Date
March 1 2023
Last Update
April 4 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuyderland Hospital
Heerlen, Netherlands, 6419 PC
2
Maastricht University Medical Center
Maastricht, Netherlands, 6202 AZ
3
MAATRO clinic
Maastricht, Netherlands, 6229 ET